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Modulation of Cell Proliferation and Cytokine Production in Acute Myeloblastic 
Leukemia by Interleukin-1 Receptor Antagonist and Lack of its Expression by 
Leukemic Cells 
By Alessandro Rambaldi, Maria Torcia, Stefania Bettoni, Edouard Vannier, Tiziano Barbui, Alan R. Shaw, 
Charles A. Dinarello, and Federico Cozzolino 
Interleukin-1 (IL-1) is spontaneously produced by acute my- 
eloblastic leukemia (AML) cells. IL-1 also induces synthesis of 
colony-stimulating factors (CSFs) and sustains leukemic 
growth. An IL-1-specific inhibitor has been recently purified 
and cloned; this molecule binds to IL-1 receptors but has no 
IL-1 activity, fulfilling the characteristics of an IL-I receptor 
antagonist (IL-lra). Because high-affinity binding sites for 
IL-lra were shown on AML cells by radioligand binding 
studies, we studied the effect of IL-lra on the proliferative 
activity of blast cells isolated from 16 cases of AML. In each 
case, spontaneous Proliferation was inhibited by addition of 
the IL-lra in a dose-dependent manner (1 to 100 ng/mL). 
Culture supernatants of unstimulated leukemic cells con- 
HE AUTONOMOUS GROWTH of cancer cells is T frequently driven by the same factors that stimulate 
normal cell proliferation. Cancer cell proliferation may 
take place in the context of autocrine circuits, whereby 
neoplastic cells produce their own growth factors and use 
them to proliferate. Growth can also occur via paracrine 
circuits, whereby they divide in response to growth factors 
released by the surrounding cells.’,* Common to both 
modalities is the interaction of ligands with specific surface 
receptors that convey the growth signal to the nuclear 
compartment. In acute myelogenous leukemia (AML), 
autocrine and paracrine loops supply the malignant cells 
with potent stimulants, such as the colony-stimulating 
factors (CSFS).”~ We and others have reported that in AML 
the autocrine production of interleukin-1 (IL-1) supports 
neoplastic growth in vitro7*’ and maintains the autocrine 
synthesis of granulocyte-macrophage CSF (GM-CSF) and 
granulocyte CSF (G-CSF).9 Studies have also shown sponta- 
neous expression of the IL-1P gene in freshly obtained 
AML cells, whereas blood leukocytes from healthy donors 
do not express this gene unless ~timulated.~ Antibodies to 
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tained IL-1s and granulocyte-macrophage CSF (GM-CSF), 
but when incubated with the IL-lra, a reduction or disappear- 
ance of GM-CSF was observed in 8 of 10 cases, whereas 
spontaneous IL-1 production was reduced in four of seven 
cases. By Northern hybridization, IL-Ip gene transcripts were 
shown in 20 of 23 AML cases, whereas IL-lra-specific messen- 
ger RNA was present in only two of the patients studied. 
These data show a role for IL-1 in the spontaneous prolifera- 
tion and cytokine production of AML cells and suggest that 
an imbalanced synthesis of IL-1 and of its natural receptor 
antagonist may contribute to the unrestricted growth of AML 
cells. 
o 1991 by The American Society of Hematology. 
IL-la and P suppress the spontaneous proliferation of 
AML  cell^.^-'^ 
A 23-Kd glycoprotein isolated from the urine of a patient 
with monocytic leukemia” was shown to inhibit a variety of 
biologic activities of IL-1. This IL-1 “inhibitor” specifically 
blocked the binding of IL-1 to its cell surface  receptor^.'^ 
Recently, this IL-1 inhibitor has been cloned and its amino 
acid sequence showed significant structural homology with 
both IL-la and P.15 The nonglycosylated form of the IL-1 
inhibitor competes with IL-1 for the binding to specific 
receptors, but is devoid of IL-1 biologic activity; accord- 
ingly, it has been renamed the IL-1 receptor antagonist 
(IL-ha). 
We therefore sought to investigate the effects of IL-lra 
on leukemic cell growth and on functional parameters of 
AML cells. In addition, because some neoplastic cells have 
been characterized by the absence of factors that reduce 
growth, we studied IL-lra gene expression in freshly ob- 
tained leukemic cells. 
MATERIALS AND METHODS 
Leukemic cells. Leukemic cells of 28 randomly selected AML 
patients were obtained from bone marrow aspirate or peripheral 
blood samples. Approval was obtained from the Institutional 
Review Board for these studies. Informed consent was provided 
according to the Declaration of Helsinki. The diagnosis of AML 
was established by morphology, cytochemical staining, and surface 
marker analysis, using a panel of antimyeloid monoclonal antibod- 
ies (MoAbs), as detailed elsewhere.’-s Leukemic cells were purified 
by Ficoll-Hypaque gradient centrifugation ( > 90% pure blasts) and 
total cellular RNA was immediately extracted as described.)-s Cell 
viability was confirmed by flow cytofluorimetry of cells stained with 
propidium iodide, 10 pgImL, for 1 hour.’6 Vials of leukemic cells of 
each patient were also cryopreserved in 10% dimethyl sulfoxide 
(DMSO) in the vapor phase of liquid nitrogen until use. 
For proliferation studies, leukemic cells were 
cultured in 96-well round-bottom microtiter plates in the presence 
or absence of different reagents at 2.5 x 105/mL in RPMI 1640 
medium, supplemented with 2 mmol/L L-glutamine and 10% fetal 
calf serum (FCS; HyClone, Logan, UT), hereafter referred to as 
complete medium. Cells were pulsed with 0.5 pCi of ’H-thymidine 
(Amersham, Little Chalfont, Buckinghamshire, UK; specific activ- 
ity, 25 Cilmmol) 12 hours before harvesting. 
Cell culture. 
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Human recombinant IL-la (IL-la) had a specific activity of 
1.3 x 10' half-maximal unitsimg in the thymocyte costimulation 
assay; this cytokine was obtained through the courtesy of Dr A. 
Galazka (Glaxo Institute for Molecular Biology, Geneva, Switzer- 
land). Human recombinant IL-lp (generously provided by Dr D. 
Boraschi, Sclavo, Siena, Italy) had a specific activity of 1 X 10' 
U/mg of protein. Human recombinant IL-lra was obtained from 
Dr R.C. Thompson (Synergen Inc, Boulder, CO); this cytokine was 
inactivated by heating at 90°C for 15 minutes. The IgG fractions of 
neutralizing sheep antisera against IL-la and p, a generous gift 
from Dr S. Poole (National Institute for Biological Standards and 
Controls, Potters Bar, UK), were obtained by affinity chromatogra- 
phy on Protein A-Sepharose columns and used at a final concentra- 
tion of 5 pg/mL. Recombinant human GM-CSF, purchased from 
Genzyme, Inc (Boston, MA), had a specific activity of 5 x 10' 
proliferation unitsimg. 
IL-la was radioiodinated using the method 
reported by Lowenthal and MacDona1d.l' The labeled protein had 
a specific activity of 0.5 mCi/mg and produced a single band of 17 
Kd in sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). For binding studies, leukemic cells, 10' per tube, 
were pretreated at pH 3.0 (RPMI 1640 medium brought to pH 3.0 
with phosphoric acid 1 mmol/L) for 1 minute at 4"C, washed, and 
resuspended in medium at pH 7.4 supplemented with 0.02% 
sodium azide. Cells were then treated with various concentrations 
of IL-la or of IL-lra for 30 minutes at room temperature, and 
finally incubated with 0.2 nmol/L '"I-IL-la for 2 hours at 4°C. 
Specific binding and percent of inhibition of specific binding to 
various concentrations of IL-lra were calculated relative to the 
control samples. 
Leukemic cells ( 10b/mL) 
were cultured in complete medium in the presence or absence of 
IL-lra for 48 hours. Supernatants were then collected and cells 
lysed through three cycles of freezing and thawing. IL-lp," 
GM-CSF," and IL-6'" were measured by specific, non-cross- 
reacting radioimmunoassays (RIA). Each RIA has been validated 
using the cytokine in their respective biologic assay. 
Total cellular RNA was electrophoresed in 
agarose gels, and blotted as previously described."s Membranes 
were hybridized with cDNA probes labeled with "P-dCTP by the 
method of Feinberg and Vogelstein." The cDNA for the IL-lra 
was obtained by polymerase chain reaction (PCR) using messenger 
RNA (mRNA) from AML-193 cells as substrate." The cells were 
treated with 4 nmol/L phorbol myristate acetate (PMA) and 1 
ng/mL GM-CSF for 24 hours before lysis and extraction of poly-A' 
RNA. PCR primers were synthesized to correspond to the 5' and 3' 
ends of the mature IL-lra coding sequence as published by 
Eisenberg et aI.l5 The IL-1p cDNA probe was a gift of Dr Steven 
Clark (Genetics Institute, Cambridge, MA). The chicken actin 
cDNA was obtained from the American Type Culture Collection 
(ATCC; Rockville, MD). 
Binding studies. 
Measurement of cytokine production. 
Northem blots. 
RESULTS 
IL-lra and IL- la  compete for binding to su$ace receptors. 
To show the existence of specific binding sites for IL-lra on 
myeloid cells, radioligand binding studies were performed. 
The percentage of binding inhibition of iodinated IL-la in 
the presence of increasing concentration of cold IL-la and 
IL-lra was evaluated. As shown in Fig 1, unlabeled IL-lra 
was only slightly less efficient than unlabeled IL-la in 
exerting a dose-dependent inhibition of '2sI-IL-1a binding 
to surface receptors, indicating the existence of high-affinity 
binding sites for IL-lra on AML cells. It should be noted 
that these data represent the binding to high-affinity IL-1 
Concentration of competitor (nM) 
Fig 1. Effect of IL-lra on binding of '251-labeled rlL-la to AML 
blasts. Binding experiments were performed incubating lo6 AML cells 
for each point with increasing concentrations of either unlabeled (0) 
rlL-la or (0)  rlL-lra in the presence of 0.2 nmol/L '251-labeled rlL-la. 
receptors on leukemic cells, which are uncovered after 
removal of the endogenous cytokine with an acid wash.' 
IL-lra inhibits spontaneous AML cell proliferation in vitro. 
On the basis of this observation, in a preliminary experi- 
ment we evaluated the effect of different concentration of 
IL-lra on the in vitro growth of blasts from three AML 
patients characterized by different levels of spontaneous 
proliferation (Fig 2). In these cases, regardless of the 
spontaneous baseline proliferation, we observed a signifi- 
cant inhibitory effect at concentrations as low as 1 ng/mL 
and up to 50 ng/mL. There was no further reduction in 
proliferation using higher doses of IL-lra. For this reason, 
13 additional AML cases were studied using a fixed 
concentration of 100 ng/mL of IL-lra. In each case, we 
could measure some inhibition of spontaneous AML cell 
proliferation ranging from 27% to 82% (Table 1). In these 
conditions, the ex vivo proliferation of AML cells depends 
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Fig 2. Dose-dependent effect of IL-lra on leukemic cell prolifera- 
tion from three different AML patients. Cells were cultured for 48 
hours at the concentration of 2.5 x 105/mL, in the presence or 
absence of the indicated stimuli. 3H-TdR was added during the last 12 
hours of culture. Results are expressed as mean cpm of triplicate 
cultures. SD was 5 10%. ( W )  Patient 1; (@) patient 2; ( 
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Table 1. Effect of IL-lra on Spontaneous Proliferation of AML Blasts 
'H-TdR Incorporation (cpm) 
Case Medium Anti-IL- 1 a 
No. Alone rlL-lra* % decrease +Anti-IL-lpt % decrease rlL-lptS 
1 10,786 3,990 63 6,540 39 25,348 
2 7,847 2,893 63 4,001 49 28,345 
3 3,180 750 76 2,110 34 8,530 
4 31,752 7,375 77 19,367 39 61,459 
5 1,201 590 51 804 34 3,980 
6 15,134 8,386 45 10,345 32 21,476 
7 20,797 12,687 39 15,890 24 28,709 
8 1,414 275 81 789 45 4,873 
9 4.41 3 1,659 62 2,234 49 16,578 
11 4,824 2,003 58 3,201 34 37,658 
12 3,262 922 72 1,756 46 7,916 
13 50,392 8,097 82 28,547 43 5 1,458 
14 1,048 204 80 260 75 4,520 
15 1,549 1,004 33 ND ND ND 
16 14,429 10,521 27 13,824 4 28,643 
Cells were cultured for48 hours at the concentration 2.5 x 105/mL in the presence or absence of the indicated stimuli. 3H-TdR was added during the 
last 12 hours of cultures. Results are expressed as mean cpm of triplicate cultures. SD was 510%. Control IgG from pre-immune sheep serum 
showed no toxicity in the proliferation assay. 
Abbreviation: ND, not determined. 
*lL-1 ra was used at the final concentration of 100 ng/mL. 
tPurified IgG from sheep anti-IL-la and anti-IL-lp antisera were used at the final concentration of 1 pg/mL. 
SrlL-1 p was used at the final concentration of 10 ng/mL. 
on the competitive interaction with the same receptor of 
two ligands: the endogenously produced IL-1 and the 
exogenously added IL-lra. The concentration of IL-1 pro- 
duced in culture is dependent on the cell number and on 
the rate of synthesis and uptake, which is particular for each 
leukemic clone.8 Experiments performed with lower num- 
bers of cells producing high amounts of IL-1 and GM-CSF 
showed inhibition of proliferation in excess of 80% (data 
not shown). 
A time course analysis showed that the inhibitory activity 
of the IL-lra on AML cell proliferation was detectable 
after 12 hours of culture and reached a plateau at 48 to 60 
hours (Fig 3). To investigate whether the effect of the 
IL-lra was reversible, AML cell proliferation was assessed 
in cultures exposed to IL-lra for 48 hours. At the end of this 
period, cells were washed and replated. At this time, cell 
viability, assessed by flow cytofluorimetry, was not signifi- 
cantly different between untreated and treated cultures. 
However, as shown in Table 2, AML blasts exposed to 
IL-lra had a strongly reduced proliferation rate, either 
spontaneous or induced by exogenous IL-1p. The exposure 
to GM-CSF was followed by a partial proliferative re- 
sponse. 
IL-Ira regulates IL-Ip and GM-CSFproduction by AML 
blasts. To investigate further the molecular mechanisms 
of action of IL-lra on leukemic cells, the spontaneous 
production of IL-lp, GM-CSF, and IL-6, in basal condi- 
tions and in the presence of IL-lra, was assessed. As 
expected from previously published constitutive 
production of cytokines was variable among the patients 
ranging for GM-CSF from a minimum of 140 pg/mL in /-/ 
80 
loo 1 
20 
0 
Table 2. Proliferation of Leukemic Cells After Removal of IL-lra 
'H-TdR Incorporation (cpm) 
Stimulus Control* IL-Ira* 
None 5,855 690 
IL-lpt 10,002 524 
GM-CSFt 36,199 2,014 
1 t 'Leukemic cells from patient no. 4 were cultured for 48 hours in the 
72 
presence of 100 ng/mL of IL-lra or of heat-inactivated IL-lra as control. 
Cells were washed and spontaneous or cytokine induced proliferation 
1 2  2 4  36 4 8  60  
Time (hours) 
Fig 3. Time-dependent effect of IL-lra on spontaneous AML 
proliferation. Leukemic blasts from patient no. 4 were cukured at 
2.5 l d / m ~  with 1 ~ )  n g / m ~  of IL-lra for the indicated times. 
was assessed after additional 48 hours by 'H-TdR incorporation. 
Results are expressed as mean cpm of triplicate culture. SD was always 
less than 10%. Data from one representative experiment of three 
Results are expressed as percentage of inhibition of SH-TdR incorpora- 
tion. 
performed are shown. 
tcytokines were used at the final concentration of 10 ng/mL. 
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patient no. 4 to a maximum of 3.6 ng/mL in the case of 
patient no. 7. Similar results were obtained with IL-lp 
where as low as 72 pg/mL was detected in the culture 
supernatants of patient no. 8. In other patients, such as nos. 
7 and 9, we could detect up to 5 ng/mL of IL-1p secreted. 
Figure 4A shows that the spontaneous release of GM-CSF 
was reduced by IL-lra in 8 of 10 cases. A similar inhibition 
of spontaneous IL-lp production by AML cells was ob- 
served (Fig 4B) in four of seven cases studied. In both 
instances, the effect was dose-dependent (data not shown). 
A similar reduction in spontaneous IL-6 production was 
also observed (data not shown). 
In the 
light of the clear-cut biologic activity of IL-lra on AML 
cells, it was important to establish whether leukemic cells 
constitutively expressed the IL-lra gene. As indicated in 
the representative Northern analysis shown in Fig 5, no 
IL-lra and I L - l p  gene expression in AML blasts. 
A 
B 
100 
80 
_lll __..... lll" ................................................... 
60 
--_I__-." ..... 
40 
20 
11 13 8 14 10 7 9 4 12 6 
100 1 
80 
60 
40 
20 
0 
11 13 8 14 10 7 9 
AML patient 
Fig 4. Effect of IL-lra on GM-CSF (A) and IL-lp (6)  production by 
AML blasts. AML cells (106/mL) from the indicated patients were 
cultured with 200 ng/mL of IL-Ira for 48 hours. GM-CSF and IL-1p 
were measured in culture supernatants by specific radioimmunoas- 
says. Results are expressed as percent of the cytokine production by 
untreated AML cells. 
IL-lra-specific mRNA could be detected in the majority of 
the cases studied (21 of 23), even after prolonged autora- 
diographic exposures. Only in two cases, of the M4 and M5 
cytologic French-American-British (FAB) subtype, could 
small but detectable amounts of IL-lra mRNA be found. 
By contrast, IL-1p gene expression was readily observed in 
20 of the 23 cases studied. These experiments were per- 
formed with RNAs purified from freshly isolated uncul- 
tured leukemic cells. We also noted that GM-CSF- 
stimulated monocytes of a healthy donor induced large 
amounts of mRNA specific for both IL-lra and IL-1p (Fig 
5) .  The induction of IL-1 inhibitory activity by GM-CSF has 
been observed previously.z2 
DISCUSSION 
The proliferation of normal hematopoietic precursors is 
controlled by several growth factors that act in an orderly 
manner.23 It is believed that in leukemic cells coordination 
between proliferation and differentiation is lost, mostly 
because of an uncontrolled supply of growth factors. In 
particular, IL-1 and GM-CSF take part in autocrinc and 
paracrine circuits that may support leukemic growth in 
vivo.' " IL-1 exerts pleiotropic and potentially harmful 
activities and its biologic effects are thereforc carefully 
controlled. One such control mechanism is likely exerted by 
the IL-lra that prevents cytokine interaction with its 
surface receptors on target cells. 
In this study we found that IL-lra could inhibit spontane- 
ous AML cell proliferation and that, in the majority of the 
cases studied, the inhibition was profound. The basis of this 
inhibition appears to be the blockade of endogenous IL-1 
binding to surface receptors. Competition experiments 
showed nearly the same affinities of both IL-la and IL-lra 
for the receptors in AML cells. As the rate of synthesis of 
IL-1 varies from patient to patient, the amounts of IL-lra 
required to obtain a significant reduction in cell growth will 
be different. 
Occupancy of IL-1 receptors as low as 10% is sufficient to 
deliver a biologic signalz4 z5; it is therefore necessary to 
completely saturatc the binding sites on the target cells to 
observe growth suppression in vitro. In view of this, the 
residual proliferative activity of IL-lra-treated leukemic 
cell cultures is probably due to the ongoing production of 
different autocrine growth factors; in fact, leukemic cells 
exposed to IL-lra partially responded to exogenous GM- 
CSF. However, the observation that they failed to prolifer- 
ate to recombinant IL-1 (rIL-1) suggests that an additional 
effect of IL-lra on blast cells may be the internalization and 
recirculation of IL-1 receptor molecules on the cell surface. 
A possible mechanism of action of IL-lra on AML cell 
growth is suggested by the experiments showing decreased 
release of GM-CSF and IL-1 by IL-lra-treated cells. 
Although spontaneous GM-CSF production is not a univer- 
sal feature in AML, it is known that other factors, such as 
G-CSF' or IL-6," can be produced by hematopoietic cells in 
an IL-1-dependent fashion, and evidence indicates that 
multiple autocrine circuits operate within a single malig- 
nant clone.z7 IL-1 appears to play a key, hierarchic role in 
each of these circuits. It is not surprising, therefore, that 
3252 RAMBALDI ET AL 
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Fig 5. Expression of IL-lra and 
IL-1p genes in AML cells. Total 
cellular RNA was purified from 
uncultured AML blasts of the in- 
dicated patients, blotted, and hy- 
bridized to the IL-lraapecific 
probe. The same blot was later 
washed and rehybridized with a 
cDNA probe for IL-1p. As a posi- 
tive control, RNA from normal 
monocytes stimulated with hu- 
man rGM-CSF (100 nglmL) was 
used. 
I_- B -  
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blocking the interaction between IL-1 and leukemic cells, 
either through neutralization of IL-1 activity or through 
prevention of IL-1 binding to receptors, results in the 
interruption of such circuits and eventually in growth 
arrest. Inhibition of growth was apparently irreversible, as 
assessed up to 5 days after removal of IL-lra, suggesting 
that interruption of autocrine loops operating in leukemic 
cells may lead to lethal consequences for malignant blasts. 
In this respect, preliminary experiments indicate that in 
some, though not all AML cases, a prolonged incubation 
(120 hours) with IL-lra is associated with a reduced 
leukemic blasts viability (data not shown). 
As previously shown by us and others, we confirmed that 
the majority of resting unstimulated AML populations 
show IL-1 gene However, under the same 
experimental conditions, we could not observe significant 
IL-lra gene expression, with the possible exception of two 
cases. The failure of AML cells to express IL-lra mRNA 
was not an absolute one in that in two cases we found low 
but detectable levels of transcription and, after in vitro 
culture in the absence of deliberate stimulation, some 
leukemic blasts from different AML patients expressed the 
IL-lra gene, even though simultaneous production of 
IL-1-specific mRNA was simultaneously increased (data 
not shown). In this respect, it has been shown that myeloid 
cell lines produce IL-1 inhibitors after in vitro stimulation 
with phorbol esters or GM-CSF?* However, in agreement 
with our results, no significant inhibitory activity could be 
detected in resting conditions. The discrepancy between 
IL-1 and IL-lra secretion by leukemic cells is somehow 
surprising, because the kinetics of gene expression of these 
cytokines in monocytes is comparable.'s 
As suggested by recent experiments performed by Bot et 
al,'" secrction of growth factors by leukemic cells probably 
reflects the amplification of a physiologic event rather than 
being leukemia-specific, because normal bone marrow cells, 
under appropriate conditions of stimulation, present a 
similar activity. The molecular dissection of autocrine and 
paracrine circuits influencing growth of normal as well as 
leukemic progenitors should provide important tools for 
manipulating hematopoiesis for therapeutic purposes. 
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